Globenewswire·2026-02-09 13:00Core Insights - 4D Molecular Therapeutics has completed enrollment for the 4FRONT-1 Phase 3 clinical trial of 4D-150 in patients with wet age-related macular degeneration (wet AMD) [1][4] - The trial achieved enrollment in approximately 11 months, exceeding initial projections and reflecting strong interest from both investigators and patients [2][4] - Topline data from the 4FRONT-1 trial is expected in the first half of 2027, with a second Phase 3 trial, 4FRONT-2, on track for completion in the second half of 2026 [4] Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics, particularly for retinal diseases [7] - The lead product candidate, 4D-150, aims to provide sustained delivery of anti-VEGF biologics through a single intravitreal injection, potentially reducing the treatment burden for patients [5][7] - The company is also developing 4D-710, a genetic medicine for cystic fibrosis, demonstrating its commitment to innovative therapeutic solutions [7] Clinical Trial Details - The 4FRONT-1 trial is a multicenter, randomized, double-masked study comparing intravitreal 4D-150 to aflibercept, with the primary endpoint being non-inferiority in best corrected visual acuity (BCVA) at 52 weeks [2][4] - The trial is specifically targeting treatment-naïve wet AMD patients across North America, with plans for supplemental aflibercept injections for participants [2][4] - The second Phase 3 trial, 4FRONT-2, will include both treatment-naïve and recently diagnosed treatment-experienced patients, with an identical design to 4FRONT-1 [4] Market Context - Wet AMD is a prevalent condition, with over 4 million individuals expected to be affected in major markets within the next five years, and 200,000 new diagnoses annually in the U.S. [6] - The disease is characterized by abnormal blood vessel growth in the retina, leading to vision loss, which underscores the need for effective treatment options [6]